Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05756764 · ClinicalTrials.gov registry record

Anti-obesity Pharmacotherapy and Inflammation

A clinical trial of Obesity, sponsored by Louisiana State University Health Sciences Center in New Orleans.

Active
Registry status
30
Enrollment target
2
Study locations

NCT05756764 is a study of Obesity that is active but no longer recruiting, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05756764, a study of Obesity, is active but no longer recruiting, sponsored by Louisiana State University Health Sciences Center in New Orleans.

ACTIVE NOT RECRUITING
Registry status
30 participants
Enrollment target
2
Study locations

Study Summary

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Conditions Studied

Interventions

  • DRUG Tirzepatide
  • DRUG Semaglutide
  • DRUG Topiramate
  • DRUG Phentermine
  • DRUG Phentermine-Topiramate combination

Study Locations (2)

Louisiana

  • LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO - New Orleans
  • Ochsner Health System - Biospecimen - New Orleans

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-06-01
Est. Completion 2026-02-20

What the Registry Record Tells You About NCT05756764

The ClinicalTrials.gov registry entry for NCT05756764 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Tirzepatide is the first listed.

NCT05756764 reports 2 study locations spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT05756764 about?

NCT05756764 is a clinical study titled "Anti-obesity Pharmacotherapy and Inflammation". This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

What is the current status of trial NCT05756764?

This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2023-06-01. Estimated completion is 2026-02-20.

What conditions does trial NCT05756764 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT05756764?

The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Topiramate (DRUG), Phentermine (DRUG), Phentermine-Topiramate combination (DRUG).

Who is sponsoring clinical trial NCT05756764?

This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05756764 being conducted?

This trial has 2 study locations across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.